| Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria C Lai, N Pursell, J Gierut, U Saxena, W Zhou, M Dills, R Diwanji, C Dutta, ... Molecular Therapy 26 (8), 1983-1995, 2018 | 100 | 2018 |
| Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I C Martin-Higueras, S Luis-Lima, E Salido Molecular Therapy 24 (4), 719-725, 2016 | 85 | 2016 |
| CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I N Zabaleta, M Barberia, C Martin-Higueras, N Zapata-Linares, I Betancor, ... Nature communications 9 (1), 5454, 2018 | 68 | 2018 |
| Molecular therapy of primary hyperoxaluria C Martin-Higueras, A Torres, E Salido Journal of Inherited Metabolic Disease 40, 481-489, 2017 | 43 | 2017 |
| Novel therapeutic approaches in primary hyperoxaluria A Weigert, C Martin-Higueras, B Hoppe Expert opinion on emerging drugs 23 (4), 349-357, 2018 | 42 | 2018 |
| A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3 C Martin-Higueras, SF Garrelfs, JW Groothoff, DE Jacob, SH Moochhala, ... Kidney International 100 (3), 621-635, 2021 | 32 | 2021 |
| DPAGT1-CDG: Functional analysis of disease-causing pathogenic mutations and role of endoplasmic reticulum stress P Yuste-Checa, AI Vega, C Martín-Higueras, C Medrano, A Gámez, ... PLoS One 12 (6), e0179456, 2017 | 27 | 2017 |
| Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1 DGM Moya-Garzon MD, Martin Higueras C, Peñalver P, Romera M, Fernandes MX ... Journal of Medicinal Chemistry, 2018 | 21 | 2018 |
| Improving treatment options for primary hyperoxaluria B Hoppe, C Martin-Higueras Drugs 82 (10), 1077-1094, 2022 | 18 | 2022 |
| Inherited conditions resulting in nephrolithiasis B Hoppe, C Martin-Higueras Current Opinion in Pediatrics 32 (2), 273-283, 2020 | 18 | 2020 |
| Targeting kidney inflammation as a new therapy for primary hyperoxaluria? C Martin-Higueras, I Ludwig-Portugall, B Hoppe, C Kurts Nephrology Dialysis Transplantation 34 (6), 908-914, 2019 | 14 | 2019 |
| Iohexol plasma clearance, a simple and reliable method to measure renal function in conscious mice S Luis-Lima, AE Rodríguez-Rodríguez, C Martín-Higueras, ... Pflügers Archiv-European Journal of Physiology 468, 1587-1594, 2016 | 14 | 2016 |
| Systemic alanine glyoxylate aminotransferase mRNA improves glyoxylate metabolism in a mouse model of primary hyperoxaluria type 1 A Kukreja, M Lasaro, C Cobaugh, C Forbes, JP Tang, X Gao, ... Nucleic acid therapeutics 29 (2), 104-113, 2019 | 12 | 2019 |
| Is stiripentol truly effective for treating primary hyperoxaluria? C Martin-Higueras, M Feldkötter, B Hoppe Clinical Kidney Journal 14 (1), 442-444, 2021 | 11 | 2021 |
| New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production MD Moya-Garzon, B Rodriguez-Rodriguez, C Martin-Higueras, ... European Journal of Medicinal Chemistry 237, 114396, 2022 | 9 | 2022 |
| Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I P Recker, BB Beck, P Sikora, H Göbel, MJ Kemper, A Nazco, ... Scientific Reports 12 (1), 16725, 2022 | 5 | 2022 |
| Diet-related urine collections: assistance in categorization of hyperoxaluria H Dill, C Martin-Higueras, B Hoppe Urolithiasis 50 (2), 141-148, 2022 | 5 | 2022 |
| CRISPR/Cas9-mediated disruption of glycolate oxidase is an efficacious and safe treatment for primary hyperoxaluria type I N Zabaleta, M Barberia, C Martin-Higueras, N Zapata, I Betancor, ... MOLECULAR THERAPY 26 (5), 384-385, 2018 | 5 | 2018 |
| Determinants of kidney failure in primary hyperoxaluria type 1: findings of the European hyperoxaluria consortium EL Metry, SF Garrelfs, LJ Deesker, C Acquaviva, V D’ambrosio, ... Kidney International Reports 8 (10), 2029-2042, 2023 | 4 | 2023 |
| siRNA therapeutics to treat liver disorders C Lai, C Martin-Higueras, E Salido Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders, 159-190, 2017 | 3 | 2017 |
Eduardo SalidoHospital Universitario Canarias, Universidad La LagunaVerified email at ull.es
